Trulicity Guide

How Trulicity Works

Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing two modified GLP-1 peptide chains to a human IgG4 Fc fragment, which extends the half-life to about five days and allows once-weekly dosing. By activating GLP-1 receptors, dulaglutide stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and modestly reduces appetite. The blood-sugar-lowering effect is the labeled indication; the weight reduction is a secondary effect that is smaller than what is seen with semaglutide or tirzepatide.^[2]

Dosing Schedule

Trulicity uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label^[1].

Side Effects

Clinical Trial Results

“

The AWARD program comprised the pivotal phase 3 trials supporting Trulicity's approval and label expansions, evaluating dulaglutide as monotherapy and in combination with metformin, sulfonylureas, insulin, and SGLT2 inhibitors across more than 10 studies. AWARD-7 (Tuttle et al. Lancet Diabetes Endocrinol 2018, PMID 29910024) took patients who had type 2 diabetes alongside chronic kidney disease of moderate-to-severe grade, and found dulaglutide noninferior to insulin glargine on HbA1c reduction while causing less weight gain and less hypoglycemia. SUSTAIN-7 (Pratley et al. Lancet Diabetes Endocrinol 2018, PMID 29397376) set once-weekly semaglutide against dulaglutide head to head: at matched dose levels semaglutide cut HbA1c further and body weight further. REWIND, the landmark cardiovascular outcomes trial (Gerstein et al. Lancet 2019, PMID 31189511), randomized 9,901 type 2 diabetes patients — most without established CVD — and showed a 12% relative reduction in major adverse cardiovascular events with dulaglutide 1.5 mg over a median follow-up of 5.4 years (HR 0.88, 95% CI 0.79–0.99). REWIND remains the largest and longest GLP-1 CVOT and the first to demonstrate CV benefit in a primary-prevention diabetes population, though the effect size was the smallest in the GLP-1 CVOT class.^[2]

Where to Get Trulicity

Sellers in our register that will dispense dulaglutide, or a compounded version of it, after an online consultation — shipped to your door.

What each seller in the register charges to start on a compounded GLP-1, cheapest at the top. Compounded dulaglutide from licensed 503A and 503B pharmacies is legal under federal compounding law^[3], and the rules have historically loosened further for any molecule sitting on the FDA Drug Shortage List^[4]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502^[5]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Trulicity Head-to-Head Comparisons

Short verdict pages setting Trulicity against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

See all drug-vs-drug verdicts.

Pivotal Trulicity Trial Walkthroughs

The trials that produced the Trulicity label, taken endpoint by endpoint, with the figures read off the source.

Ranked PubMed Studies on Trulicity

The peer-reviewed studies on Trulicity and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

Related Research on Trulicity

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

Frequently Asked Questions